Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UWD-19
- Development stage
- Phase 2
- Lead developer
- Shenzhen Wandao Cell Technology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
UWD-19 (also referred to as REVO-UWD-19 or UWD-CD19) is a universal CD19-targeted chimeric antigen receptor T cell (CAR-T) therapy developed by Wondercel Therapeutics. It is designed for the treatment of B cell tumors, including B cell malignancies such as refractory and relapsed B-cell tumors. As a universal CAR-T therapy, it aims to provide an off-the-shelf cellular immunotherapy option targeting the CD19 antigen expressed on malignant B cells[1][2]. The product is currently in early clinical development.
- Other names
- REVO-UWD-19REVO-UWD19REVO-UWD 19UWD-CD19UWD-CD-19UWD-CD 19
02
Targets
Beyond the preview
Go deeper on UWD-19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UWD-19.